Clinical Trial Info
Title: A Phase II Pilot Study of Dovitinib (TKI258) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma
This is an open-label, single-arm pilot study designed to obtain preliminary data on the efficacy of dovitinib in patients with recurrent or metastatic ACC. Patients will be treated with dovitinib 500 mg orally on a 5-days on/2-days off schedule for each week of a 4-week (28-day) cycle. Treatment will continue until progression as defined by RECIST, unacceptable adverse events, patient refusal to continue on study, or physician’s decision to withdraw the patient. Response will be assessed on day 26 of cycle 2, cycle 4, and every four cycles thereafter. At the end of the treatment period, patients will be followed every 4 months for 1 year. Twenty-one eligible patients will be enrolled in the study.
For more information click here, or contact the clinical research coordinator:
Ph: 434-243-6757, FAX 434-243-6069